Abstract
Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor / scatter factor (HGF / SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF / SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF / SF and c-Met function in health and disease.
Keywords: c-met, hgf/sf, hprc, missense mutations, renal carcinoma
Current Molecular Medicine
Title: Hereditary Papillary Renal Carcinoma Type I
Volume: 4 Issue: 8
Author(s): Pathirage G. Dharmawardana, Alessio Giubellino and Donald P. Bottaro
Affiliation:
Keywords: c-met, hgf/sf, hprc, missense mutations, renal carcinoma
Abstract: Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor / scatter factor (HGF / SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF / SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF / SF and c-Met function in health and disease.
Export Options
About this article
Cite this article as:
Dharmawardana G. Pathirage, Giubellino Alessio and Bottaro P. Donald, Hereditary Papillary Renal Carcinoma Type I, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359674
DOI https://dx.doi.org/10.2174/1566524043359674 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Current Pharmaceutical Design Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Role of microRNAs in Gynecological Pathology
Current Medicinal Chemistry Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Current Cancer Drug Targets Mitochondria-Targeting Anticancer Metal Complexes
Current Medicinal Chemistry Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Synthetic Survey and Activity of 2'-deoxy-methanocarba Nucleosides
Current Organic Synthesis Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics The Role of Wnt/Beta-Catenin Signaling in Renal Carcinogenesis: Lessons from Cadmium Toxicity Studies
Current Molecular Medicine Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine